The Complaint alleges that during the Class Period, Defendants consistently touted Inari’s “record revenue,” purportedly driven by “the strength in our core VTE business” while failing to disclose that a significant portion of its expenses were used to compensate medical professionals improperly for using Inari’s products. The Complaint further alleges that the Company had been unlawfully compensating health care professionals in violation of the federal Anti-Kickback Statute and Civil False Claims Act and had misled investors regarding business expenses in order to conceal their illicit conduct.